Skip to content

    Amylyx Pharmaceuticals (AMLX) stock price & financials

    View AMLX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+267.6% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $416.0K
    -$665.0K
    $0
    $0
    $0
    -100.0%
    $0
    +100.0%
    Strengthening
    Operating Profit
    -$75.66M
    -$40.65M
    -$37.80M
    -$42.86M
    -$36.03M
    +52.4%
    -$36.60M
    +10.0%
    -$43.78M
    -15.8%
    -$45.69M
    -6.6%
    Weakening
    Net Profit
    -$72.70M
    -$37.55M
    -$35.91M
    -$41.44M
    -$34.39M
    +52.7%
    -$33.00M
    +12.1%
    -$41.28M
    -15.0%
    -$43.42M
    -4.8%
    Stable
    EPS
    $-1.07
    $-0.42
    $-0.46
    $-0.37
    +65.4%
    $-0.37
    +11.9%
    $-0.39
    +15.2%
    Strengthening
    Other Income
    $2.96M
    $2.47M
    $1.90M
    $1.41M
    $1.64M
    -44.5%
    $3.65M
    +47.6%
    $2.50M
    +31.6%
    $2.27M
    +60.5%
    Strengthening
    Interest
    Depreciation
    Profit before Tax
    -$72.70M
    -$38.18M
    -$35.91M
    -$41.44M
    -$34.39M
    +52.7%
    -$32.95M
    +13.7%
    Strengthening
    MarginsOPM
    -18187.7%
    6113.4%
    Tax
    0.0%
    1.7%
    0.0%
    0.0%
    0.0%
    -0.1%
    -108.4%
    Weakening
    ReturnsROIC
    7.0%
    3.6%
    3.5%
    4.0%
    3.3%
    -52.7%
    3.2%
    -12.1%
    4.0%
    +15.0%
    4.2%
    +4.8%
    Stable

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$50.19M$62.53M$170.20M$77.39M$226.65M$49.33M
    Short-Term Investments$201.16M$99.11M$90.33M$201.43M
    Total Current Assets$104.95M$382.13M$464.67M$189.43M$323.67M$256.34M
    Net PP&E$474.0K$8.13M$6.41M$2.73M$5.49M$4.74M
    Goodwill
    Intangibles
    Total Assets$105.61M$391.45M$517.45M$193.63M$332.64M$264.56M
    LiabilitiesTotal Current Liabilities$17.40M$46.61M$82.04M$28.41M$22.69M$21.15M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$4.24M$1.98M$463.0K$4.70M$4.25M
    Total Liabilities$17.43M$50.85M$84.02M$28.87M$27.39M$25.40M
    EquityCommon Stock & APIC$1.0K$7.0K$7.0K$7.0K$11.0K$11.0K
    Retained Earnings-$155.84M-$354.22M-$304.95M-$606.69M-$751.43M-$836.13M
    Total Equity-$151.17M$340.61M$433.43M$164.76M$305.26M$239.17M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$74.80M-$179.87M$11.92M-$167.65M-$123.34M-$126.58M
    Cash from Investing-$46.41M-$238.99M$92.05M$75.65M$14.04M-$78.83M
    Cash from Financing$158.51M$431.79M$3.54M$348.0K$257.03M$196.09M
    SummaryCapital Expenditure-$353.0K-$2.53M-$1.24M-$157.0K-$138.0K
    Free Cash Flow-$75.15M-$182.40M$10.68M-$167.80M-$123.48M
    FCF Margin-26369.1%-820.5%2.8%-192.1%

    Ratios